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Abstract
We recently described a pro-inﬂammatory gene expression signature in the monocytes of 60% of patients
with recent-onset schizophrenia (SCZ). Here we investigated whether the T-cell system is also in a pro-
inﬂammatory state. A detailed ﬂuorescence-activated cell sorting (FACS) analysis, e.g. of CD3+CD25+
T cells, IFN-c+, IL-4+, IL-17A+ (CD4+) lymphocytes and CD4+CD25highFoxP3+ regulatory T cells, was
performed on peripheral blood of 26 patients with recent-onset SCZ (in 19 of whom the inﬂammatory gene
expression signature of the monocyte had been determined) and in age-/gender-matched healthy con-
trols. Various relevant T-cell cytokines, e.g. sCD25, IFN-c, IL-17A and IL-4, were measured in serum by a
multiplex assay. We detected : (a) not only higher percentages of pro-inﬂammatory-prone monocytes,
activated CD3+CD25+ T cells and pro-inﬂammatory Th17 cells in patients, but also higher percentages of
anti-inﬂammatory CD4+CD25highFoxP3+ regulatory T cells and IL-4+ lymphocytes ; (b) that this activated
T-cell set point was reﬂected in signiﬁcantly raised serum levels of sCD25; (c) that the up-regulation of
IL-4+-containing lymphocytes was predominantly found in patients characterized by a monocyte pro-
inﬂammatory set point ; and (d) that regulatory T-cell and Th17-cell numbers were higher in patients
irrespective of the pro-inﬂammatory state of the monocytes. Our data do not support the concept that the
T-cell system is in a simple pro-inﬂammatory state in recent-onset SCZ, but do show that the monocyte
and T-cell networks are activated and involve both pro- and anti-inﬂammatory forces. This suggests
control within an activated inﬂammatory system.
Received 10 September 2010 ; Reviewed 10 November 2010 ; Revised 22 November 2010 ;
Accepted 17 December 2010 ; First published online 24 January 2011
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Introduction
There is accumulating evidence that activation of the
inﬂammatory response system plays an important role
in the pathogenesis of schizophrenia (SCZ). In support
of this view we recently described an inﬂammatory
gene expression signature, i.e. a coherent aberrant
expression of a set of 34 pro-inﬂammatory genes, in
the circulating monocytes of around 60% of patients
with recent-onset SCZ (Drexhage et al. 2010b).
Apart from cells of the monocyte lineage, T cells are
important contributors to the inﬂammatory response,
but literature on T-cell numbers and cytokines is
scarce and conjectural in SCZ. Although it has been
shown (Denicoﬀ et al. 1987) that infusion with IL-2, the
well-known growth factor for T cells, is capable of in-
ducing psychosis-related symptoms in psychiatrically
Address for correspondence : Mrs R. C. Drexhage, Department of
Immunology, Erasmus MC, PO Box 2040, 3000 CA, Rotterdam,
The Netherlands.
Tel. : 0031 10 7044091 Fax : 0031 10 7044731
Email : r.drexhage@erasmusmc.nl




by University Library user
on 13 June 2018
healthy individuals, there are at present inconclusive
results on the levels of IL-2 or its soluble receptor
(sIL-2R, synonymous to sCD25) in the circulation of
SCZ patients (Drexhage et al. 2010a). The same holds
true for the blood levels of IFN-c and IL-4, the hall-
mark cytokines of the CD4+Th1 and Th2 cell subsets,
respectively ; higher (Kaminska et al. 2001 ; O’Brien
et al. 2008), lower (Kim et al. 2009) or unaltered
(Kim et al. 2004) levels of these cytokines and T-cell
subsets have been described in SCZ patients.
In recent years a new pro-inﬂammatory T-cell
cytokine IL-17, has been discovered predominantly
produced by so-called CD4+ ‘Th17 cells ’ (Bettelli et al.
2008). Th17 cells protect the host against bacteria and
fungi by activating macrophages via the production
of IL-17 (and also IL-21 and IL-22). In contrast, they
also play a role in the pathogenesis of autoimmune
diseases such as psoriasis and rheumatoid arthritis
(Bettelli et al. 2008). Functions of Th17 cells are thus
similar to those of Th1 cells.
The inﬂammation-inducing eﬀects of Th17, Th1
cells and of monocytes/macrophages are controlled
by a special class of T cells, i.e. the regulatory
CD4+CD25highFoxP3+ T cells (Hori et al. 2003 ; Wing
& Sakaguchi, 2010). The main function of these inborn,
thymus-derived regulatory T cells is to temper the
inﬂammatory response thereby maintaining home-
ostasis and tolerance to self-antigens. The cytokines
involved in this anti-inﬂammatory action are thought
to be IL-10 and TGF-b. Patients lacking these regulat-
ory T cells due to a genetic mutation in the gene
coding for FoxP3 suﬀer from a severe and rapidly
lethal autoimmune syndrome (immune dysregulation,
polyendocrinopathy, enteropathy X-linked syndrome)
(Wildin et al. 2002).
The aim of this study was to evaluate T-cell-related
inﬂammatory networks in SCZ following the hypoth-
esis that not only the monocyte system, but also the
T-cell system would be in a pro-inﬂammatory state.
We therefore determined the percentages of IL-2r
(CD25+) T cells and of IFN-c-, IL-4- and IL-17A con-
taining blood lymphocytes in the circulation of 26
recent-onset patients, using intracellular staining and
ﬂuorescence-activated cell sorting (FACS) analysis. In
addition we determined with FACS the percentage of
the anti-inﬂammatory regulatory CD4+CD25highFoxP3+
T cells.
Following these FACS analyses we evaluated
the serum levels of the catabolic pro-inﬂammatory
T-cell cytokines IFN-c, IL-17A, IL-22 (and also of
the monocyte/macrophage cytokines CCL2, TNF-a,
IL-1b, PTX3) and of the anabolic or anti-inﬂammatory
cytokines sCD25, TGF-b, IL-10, IL-6, IL-4 and IL-5.
In 19 of the tested patients the monocyte inﬂam-
matory gene proﬁles had been determined in the
above-mentioned previously reported study (Drexhage
et al. 2010b). This enabled us to not only relate the
T-cell pro-inﬂammatory and anti-inﬂammatory state
to various clinical variables which we measured in
the patients [e.g. the global assessment of functioning
(GAF) score, medication, smoking], but also to the pro-
inﬂammatory state of their monocytes.
Methods
SCZ patients
Twenty-six acutely psychotic in-patients with SCZ
diagnosed according to DSM-IV criteria were re-
cruited at the department of Psychiatry of the Erasmus
Medical Centre in Rotterdam. SCZ was diagnosed ac-
cording to the DSM-IV criteria after a Comprehensive
Assessment of Symptoms and History (CASH) inter-
view (Andreasen et al. 1992) and by consensus be-
tween two senior psychiatrists who were blinded to
the results based on all clinical available evidence.
In patients with symptoms for <6 months, a ﬁnal
diagnosis was made after 6 months to comply with the
DSM-IV criterion. All patients were acutely psychotic
on admission. The patients level of functioning on
admission and at discharge was determined by the
GAF score on the ﬁfth axis of DSM-IV.
The SCZ patients were virtually all (except one)
recent-onset cases and had a median duration of ill-
ness of only 0.3 yr (median, range 0–3 yr). Absence of
severe medical illness (including infections and aller-
gies) was established by medical history assessment,
physical examination and routine laboratory testing
(Hb, Ht, leukocyte count, blood smear, kidney/liver
function) on admission. Almost all patients were
receiving antipsychotic medication at the time of
blood draw; however, with a low lifetime cumulative
haloperidol equivalent (median 42 mg Hal equiv.)
(Cahn et al. 2002) none of the patients were drug naive.
The demographics of the patients are summarized
in Table 1.
Healthy controls (HC)
Age- and gender-matched HC (Table 1) were recruited
from laboratory staﬀ, medical staﬀ and medical
students. The inclusion criteria for HC were an ab-
sence of any psychiatric and autoimmune disorder in
themselves and in ﬁrst-degree relatives. HC had to be
in self-proclaimed good health and free of any obvious
medical illness for at least 2 wk prior to blood draw,
including acute infections and allergic reactions.
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The Medical Ethical Review Committee of the
Erasmus MC Rotterdam approved the study. Written
informed consent was obtained from all participants
after a complete description of the study had been
given.
Laboratory methods
Blood collection and preparation
Blood (drawn in the morning hours) was collected
in clotting tubes for serum preparation (stored at
x80 xC) and in sodium-heparin tubes for immune cell
preparation, on average 20 ml blood was collected
from each patient. From the heparinized blood, per-
ipheral blood mononuclear cell (PBMC) suspensions
were prepared by low-density gradient centrifugation,
as described in detail elsewhere (Knijﬀ et al. 2006),
within 8 h to avoid activation of the monocytes
(erythrophagy). PBMCs were frozen in 10% DMSO
and stored in liquid nitrogen. This enabled us to test
patient and control immune cells in the same series of
experiments performed later.
Flow cytometric analyses
FACS analysis was used to measure intracellular
cytokine content in PBMC of patients and age- and
gender-matched HC. As hallmark intracellular cyto-
kines we used: IFN-c, IL-4 and IL-17A. To enable the
enumeration of regulatory T cells we intracellularly
stained for FoxP3. Membrane staining was done for
CD3, CD4, CD25 and CD45RO. This enabled us to
assign cytokine staining to the enigmatic Th1, Th2 and
Th17 cells in either the total population of CD4+ cells
or the memory population. It also enabled us to enu-
merate the enigmatic regulatory CD4+CD25highFoxP3+
T-cell population.
For the analysis PBMCs were suspended in
complete culture medium. Cell suspensions were then
stimulated with PMA (Sigma Aldrich, USA), iono-
mycin (Sigma Aldrich) in the presence of Golgistop
(Becton Dickinson, USA) for 4 h in 37 xC under a 5%
CO2 environment for T eﬀector cells, regulatory T cells
were not stimulated.
Cells were harvested and stained extracellularly
with anti-CD4 (PerCP-Cy5.5 ; Becton Dickinson) and
anti-CD45RO FITC (Dako, Denmark). For determi-
nation of regulatory T cells, non-stimulated PBMC
samples were stained with anti-CD3 (PerCP; BD
Biosciences, USA), anti-CD4 (APC; BD Biosciences)
and anti-CD25 (FITC; BD Biosciences) according to
standard protocol.
Following extracellular staining, the cells were ﬁxed
and permeabilized according to the manufacturer’s
instructions (eBioscience, USA) and then stained
for FoxP3 (PE; Becton Dickinson), IL-4 (PE; Becton
Dickinson), IFN-c (APC; Becton Dickinson), IL-17A
(PE; eBioscience).
Isotype antibody controls were used to conﬁrm
antibody speciﬁcity for CD25. Stained cells were
analysed by four-colour ﬂow cytometry (FACSCalibur,
BD Biosciences) as described previously and analysed
using FlowJo (Tree Star Inc., USA) research software.
Supplementary Fig. 1 (available online) gives the
dot plots of the stainings and deﬁnition of cell popu-
lations.
mRNA gene expression in monocytes
The deﬁnition and determination of mRNA gene
expression ﬁngerprints in monocytes has been pre-
viously described in detail (Drexhage et al. 2010b).
Serum cytokine determinations
Serum cytokines (IFN-c, IL-17, IL-10, IL-6, IL-4,
TNF-a, CCL2, IL-5, IL-1b, PTX3) were measured using
the Cytometric Bead Array kits (BenderMedSystems,
USA) according to the manufacturer’s protocol. Bead
ﬂow cytometry allows the simultaneous quantiﬁcation
of various proteins in the same test (http://www.
bendermedsystems.com/bm_ﬁles/47/BM_Factsheet_
3_A4_SCREEN.pdf). Twenty-ﬁve ml of serum per
test were used. Samples were analysed in a
FACSCanto ﬂow cytometer (BD Biosciences) using the





Group size 26 26
Age (yr)a 24 (17–39) 25 (21–39)
Gender
Male 23 (88%) 23 (88%)
Female 3 (12%) 3 (12%)
Smoking 18 (69%) 9 (35%)
GAF scorea
On admission 21–30 (1–10, 41–50)





GAF, Global assessment of functioning. GAF range from 0 to
100, higher scores indicate better functioning.
aMedian with range.
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FlowCytomix Pro 2.3 Software (BenderMedSystems).
Results are expressed as picograms per millilitre.
For TGF-b (Diaclone, France) and sIL-2r (R & D
Systems, USA) commercially available ELISAs were
used according to the manufacturer’s protocol.
Statistics
Statistical analysis was performed using the SPSS 15.0
package for Windows (SPSS Inc., USA). Data were
tested for normal distribution using the Kolmogorov–
Smirnov test. Parametric tests were used when the
data had a normal distribution. When normal distri-
bution was not reached, data were log-transformed.
If the data were still skewed after log-transformation,
non-parametric tests were used. In the text, tables
and ﬁgures the original data have been used. Levels
of signiﬁcance were set at p=0.05 (two-tailed). The
speciﬁc tests used are mentioned in the tables and
ﬁgure legends.
Results
Percentages of monocytes and lymphocytes
FACS analysis of the samples showed that the
percentage of monocytes was higher in SCZ samples
compared to those of the gender- and age-matched HC
(SCZ: 24.33¡7.91 ; HC: 20.64¡4.52 ; p=0.049, Mann–
Whitney test). Although the percentage of lympho-
cytes was smaller in the SCZ samples compared to
the HC, values did not reach statistical signiﬁcance
(SCZ: 70.97¡7.90 ; HC: 75.08¡5.02 ; p=0.077, Mann–
Whitney test). Blood leukocyte counts were within the
normal range on admission for all patients (routine
clinical determination, mean 6.4¡1.5r10.9/l, refer-
ence range for our centre : 3.5–10.0r10.9/l).
IFN-c-, IL-4- and IL-17A-containing lymphocytes
Using FACS we ﬁrst analysed the capability of the
total lymphocyte fraction to produce IFN-c, IL-4 and
IL-17A. After stimulation with PMA and ionomycin
for 4 h (a procedure to re-activate lymphocytes),
the percentages of IFN-c- and IL-17A-containing
lymphocytes were not diﬀerent between SCZ samples
and HC samples : IFN-c (SCZ: 24.47¡7.60 ; HC:
27.63¡9.45 ; p=0.199) ; IL-17A (SCZ: 0.39¡0.29 ; HC:
0.27¡0.12 ; p=0.137). However, lymphocytes capable
of producing IL-4 were more numerous in SCZ
patients compared to lymphocytes of HC (Fig. 1a).
Diﬀerences could not be detected with regard to the
mean ﬂuorescence intensity (MFI), which reﬂects the
actual content of the cytokine per lymphocyte.
CD3+CD25+ cells
Activation of T cells is classically determined by CD25
(IL-2r) expression, illustrating the higher capability of
T cells to react to the growth factor IL-2. Percentages
of CD3+CD25+ T cells were higher in SCZ patients
compared to HC (Fig. 1c). Moreover, serum levels
of the shed receptor, sCD25 (=sIL-2r), were also
higher in SCZ patients and correlated positively with
CD3+CD25+ T cells (r=0.394, p=0.007) and IL-4-
containing lymphocytes (r=0.462, p=0.001).
Classical Th1 (CD4+IFN-c+), Th2 (CD4+IL-4+),
Th17 (CD4+IL-17A+) and regulatory
CD4+CD25highFoxP3+ T cells
We subsequently studied the percentages of classical
Th1 cells (CD4+ T cells capable of producing IFN-c),
classical Th2 cells (CD4+ T cells capable of producing
IL-4) or classical Th17 cells (CD4+ T cells capable of
producing IL-17A).
The percentage of classical Th1 cells was not
diﬀerent in SCZ patients (SCZ: 7.55¡4.19 ; HC:
7.30¡3.50 ; p=0.905), while that of classical Th2
cells showed a trend to be higher in line with the
ﬁnding that IL-4-producing lymphocytes were higher
(Fig. 1b).
Statistically, higher percentages of classical Th17
cells were found in the circulation of SCZ patients
compared to that of HC (Fig. 1d). Virtually all these
Th17 cells were of memory type, i.e. they were
CD45RO+.
Figure 1e also shows that CD4+CD25highFoxP3+
T-cell (regulatory T cells) percentages were higher in
SCZ patients compared to HC (Fig. 1e). There was a
strong positive correlation between the percentage of
regulatory T cells and the serum levels of sIL-2R in the
patients (r=0.447, p=0.002).
Correlations between the diﬀerent T-cell subsets
(Table 2)
The percentages of CD3+CD25+ cells correlated sig-
niﬁcantly with the percentages of regulatory T cells,
classical Th1 cells and Th17 cells, but not with Th2
cells. Percentages of Th17 cells correlated with those of
Th1 cells, but not with Th2 cells. The percentages of
regulatory T cells did not correlate with those of Th17
cells. There was also no correlation for regulatory
T cells and Th1 or Th2 cells. Although the correlation
coeﬃcient was negative for the correlation between
Th1 and Th2 cells (as could be expected from the re-
ciprocal character of the subsets), values did not reach
statistical signiﬁcance.
T cells in schizophrenia 749
Downloaded from https://academic.oup.com/ijnp/article-abstract/14/6/746/916243
by University Library user
on 13 June 2018
Pro-inﬂammatory and anti-inﬂammatory cytokines
in serum
Levels of IFN-c, IL-17, IL-10, IL-6, IL-4 and TNF-a
were lower than the detection limit in the serum of
patients and controls (Table 3).
Levels of CCL2, IL-5, IL-1b and PTX3 were
detectable, but levels were not diﬀerent in the
serum of SCZ patients compared to those of
HC. Levels of the Th17-related cytokine IL-22 and
of the regulatory T-cell-related cytokine TGF-b
were higher in the serum of SCZ patients ;
HC SCZ Sign+ Sign– HC SCZ Sign+ Sign–
HC SCZ Sign+ Sign–
HC SCZ Sign+ Sign–





















































(a) IL-4 containing lymphocytes (b) Th2
(c) CD3+CD25+ (d) Th17

























Fig. 1. Fluorescence-activated cell sorting (FACS) analysis data of the diﬀerent subsets tested. Each symbol represents an
individual patient, the bar represents the median. * p<0.05 ; HC, healthy controls ; SCZ, schizophrenia ; Sign+, SCZ patients with
a positive signature ; Signx, SCZ patients with a negative signature. For the comparison of HC vs. SCZ p values were tested by
linear regression on log-transformed data with age and gender in the model. For the comparison of signature-positive vs.
signature-negative vs. HC p values were tested by linear regression on log-transformed data. Positive monocyte mRNA gene
expression inﬂammatory signature is deﬁned aso9 genes out of 20 tested genes positive ; positivity of a gene is deﬁned as
>1 standard deviation (S.D.) higher expressed than the mean expression of the tested gene in HC. Percentages expressed as
mean¡S.D. IL-4-containing lymphocytes (SCZ: 2.27¡0.76 ; HC: 1.82¡0.61, p=0.015 ; Sign+ : 2.51¡0.93 ; Signx : 1.91¡0.35,
p=0.013). Th2 (SCZ: 3.65¡1.14 ; HC: 3.23¡0.90, p=0.124 ; Sign+ : 4.18¡1.12 ; Signx : 3.29¡1.00, p=0.006). CD3+CD25+ T cells
(SCZ: 11.01¡3.79 ; HC: 8.32¡2.01, p=0.002 ; Sign+ : 10.25¡4.75 ; Signx : 10.95¡2.25, p=0.029). Th17 (SCZ: 0.56¡0.42 ;
HC: 0.34¡0.18, p=0.042 ; Sign+ : 0.38¡0.25 ; Signx : 0.56¡0.41). CD4+CD25highFoxP3+ T cell (SCZ: 3.01¡0.84 ; HC: 2.57¡0.65,
p=0.032 ; Sign+ : 3.01¡3.30¡0.85, p=0.043).
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however, levels did not reach statistical signiﬁcance
(Table 3).
We were unable to ﬁnd correlations between the
cytokines listed in this section and the percentages of
the various T-cell subsets.
Relation of T-cell inﬂammatory parameters to
clinical variables
We were unable to ﬁnd any correlation between the
T-cell variables reported here and antipsychotic drugs,
smoking, positive symptoms, negative symptoms or
GAF score on admission.
A positive correlation was found between the level
of functioning of SCZ patients at discharge and their
regulatory T-cell percentages on admission (Fig. 2).
Patients with regulatory T-cell percentages >3.25%
(n=16) on admission all had a GAF score of o50 at
discharge, whereas all patients (n=7) with regulatory
T-cell percentages<3.25% had a GAF score off49 at
discharge (GAF score at discharge for three patients
was not available). This led to a positive correlation
between regulatory T-cell percentage on admission
and GAF score at discharge (r=0.442, p=0.035, with
Bonferroni correction for six tests statistical signiﬁ-
cance was not reached).
Relation of T-cell inﬂammatory parameters to the
pro-inﬂammatory state of patient monocytes
Samples of 19 of the monocyte pro-inﬂammatory sig-
nature-tested patients could also be used in the pres-
ent study and in 11/19 of these patients the signature
was present compared to 3/23 of the HC [see legend
of Supplementary Fig. 2 (online) for deﬁnition of a
positive signature].
The higher percentages of IL-4-containing lympho-
cytes and of classical Th2 cells found in our
SCZ patients were largely conﬁned to SCZ patients
with a positive monocyte pro-inﬂammatory signature
(Fig. 1a, b, Supplementary Fig. 2).
The higher percentages of Th17 cells, regulatory
T cells and CD3+CD25+ cells were found in both
monocyte signature-positive and signature-negative
SCZ patients. In the signature-negative patients sig-
niﬁcantly higher percentages of regulatory T cells and
CD3+CD25+ cells were found (Fig. 1c–e).
Discussion
This study shows a strongly activated set point of the
T-cell and monocyte inﬂammatory network in patients
with recent-onset SCZ. On the one hand an activation
of pro-inﬂammatory forces was found, i.e. higher
percentages of circulating monocytes with a pro-
inﬂammatory gene expression signature, activated
(CD3+CD25+) T cells and pro-inﬂammatory Th17
cells, on the other hand there was also an activation
of anti-inﬂammatory forces, i.e. increases in CD4+
CD25highFoxP3+ T cells and IL-4-containing lympho-
cytes.
The up-regulation of IL-4-containing lymphocytes
and of classical Th2 cells, i.e. the CD4+ population
of IL-4-containing lymphocytes, was predominantly
found in SCZ patients characterized by a monocyte
Table 2. Correlations between the diﬀerent T-cell subsets





0.411** 0.202 x0.205 0.460** 0.170 x0.218 0.052 r Th1
0.002 0.155 0.149 0.001 0.223 0.116 0.712 p
0.081 x0.089 0.441** 0.092 x0.020 0.089 r Th17
0.571 0.534 0.001 0.512 0.889 0.526 p
x0.961** x0.255 x0.097 x0.223 x0.075 r Lymphocytes
0.000 0.071 0.499 0.116 0.600 p
0.200 0.063 0.189 0.054 r Monocytes
0.160 0.662 0.184 0.705 p
0.548** 0.232 0.516** r CD3CD25+
0.000 0.094 0.000 p
0.653** 0.397** r IL4-containing
0.000 0.003 p lymphocytes
0.123 r Th2
0.382 p
r=correlation coeﬃcient ; p values were tested by Pearson’s correlation on log-transformed data.
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pro-inﬂammatory gene expression set point. This
constellation of the co-occurrence of pro-inﬂamma-
tory-prone monocytes with higher percentages of
IL-4-containing lymphocytes is counterintuitive, since
IL-4 dampens the inﬂammatory state of monocytes
and macrophages, turning the cells in so-called M2
cells (Mantovani et al. 2004). We interpret our data
by hypothesizing that the higher percentage of IL-4-
containing lymphocytes in these monocyte gene
expression signature-positive patients serves as a
control mechanism to counteract monocyte suscepti-
bility for inﬂammation by keeping an actual higher
production of inﬂammatory monocyte cytokines
under control. This interpretation might then explain
the normal serum levels of the pro-inﬂammatory
monocyte/macrophage cytokines CCL2, IL-1b and
PTX3 we found in our patients. On the other hand,
preliminary data of our group (to be published) in a
cohort of older (on average 40 yr) patients with
chronic naturalistically treated SCZ showed a much
lower inﬂammatory monocyte gene expression than
reported here for acute SCZ, while serum levels of in-
ﬂammatory cytokines were clearly raised in the group
of older patients, but – apart from disease – also linked
to obesity and serum lipid levels. This indicates a clear
and incongruent role for disease duration, treatment,
activity and/or diet/obesity in the inﬂammatory
proﬁles of circulating cells and cytokine levels. This
indicates further studies for biomarker development
being required to control for these variables, un-
fortunately in this study we were had no information
on metabolic parameters of patients and controls and
were therefore unable to adjust for this.
Increases in both the pro-inﬂammatory subset of
Th17 cells and in the anti-inﬂammatory subset of
regulatory T cells in SCZ patients were found ir-
respective of the monocyte pro-inﬂammatory state
(although a little more obvious in the negative sig-
natures). Increases in the regulatory T cells and Th17
Table 3. Cytokine levels in serum
Schizophrenia Healthy controls p value
Monocyte activation CCL2 33.39 (12.46–60.30) 25.74 (14.10–60.90) 0.495
IL-1b 0.02 (0–0.55) 0.05 (0–2.55) 0.447
PTX3 66.50 (7.36–381.49) 73.07 (13.90–368.80) 0.493
IL-6 n.d. n.d.
TNFa n.d. n.d.
T-cell proliferation activity sIL-2R 1960¡593 1496¡473 0.009
Th1 IFN-c n.d. n.d.
Th2 IL-5 0.05 (0–0.41) 0.01 (0–2.69) 0.281
IL-4 n.d. n.d.
Th17 IL-22 47.43 (41.17–94.38) 45.34 (41.17–59.98) 0.265
IL-17a n.d. n.d.
Regulatory T cells TGF-b 13 872 (7602–68 981) 12 655 (4761–23 198) 0.204
IL-10 n.d. n.d.
n.d., Not detected.
Levels of cytokines are expressed as median with range. All values are in picograms per millilitre. Normal distribution was not
obtained after log-transformation. The p values were calculated by Mann–Whitney tests.
sIL-2r had a normal distribution and the level is expressed as mean¡standard deviation in IU/ml. The p value was calculated by










GAF <50 GAF >50
After discharge
p = 0.012
Fig. 2. Relation of regulatory T cell percentage on admission
and GAF score at discharge. GAF, Global assessment of
functioning ; % Tregs, percentage of CD4
+CD25highFoxP3+
cells on admission; p values were tested by linear regression
on log-transformed values (p=0.012, d.f.=21).
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cells also correlated with increased numbers of
CD3+CD25+ T cells and higher levels of serum
sCD25. Although we interpret these CD25 data as
reﬂecting a higher tendency for T-cell proliferation,
which might then underlie the higher percentages of
Th17 and regulatory T cells, there are data in the
literature which show that T-cell proliferation is in fact
reduced in acute forms of SCZ when T cells were
stimulated with anti-CD3 (Craddock et al. 2007).
That study also found a normal expression of CD25
on CD4+T cells in SCZ patients. Further studies are
needed to clarify this issue.
There is strong evidence that Th17 cells are inﬂam-
mation-promoting cells in chronic inﬂammatory con-
ditions such as rheumatoid arthritis, asthma, psoriasis
and multiple sclerosis and the number of Th17 cells as
well as the levels of the Th17-derived cytokines IL-17,
IL-21 and IL-22 are higher in aﬀected tissues (Crome
et al. 2010). Although SCZ patients do have molecular
alterations in their brain vasculature (Harris et al.
2008), it is unknown whether Th17 cells or the Th17
cytokines pass the blood–brain barrier to exert an
eﬀect. In a mouse model of multiple sclerosis Th17
cells do migrate into the brain (Reboldi et al. 2009).
Studies on post-mortem brains of SCZ patients and
animal models of SCZ-like disease could prove in-
strumental in solving this question of Th17 inﬂuence
on behaviour.
There is ample evidence that regulatory T cells are
capable of dampening the eﬀect of Th17 cells (Crome
et al. 2010), Th1 cells (Wing & Sakaguchi, 2010) and
pro-inﬂammatory monocytes (Tiemessen et al. 2007)
in immune reactions. It is therefore tempting to hy-
pothesize that the increase in anti-inﬂammatory regu-
latory T cells is meant (like that proposed for the
IL-4-containing lymphocytes) to keep under control
the pro-inﬂammatory immune forces in SCZ patients.
Another point of interest with regard to both the
rise in Th17 cells and regulatory T cells is that the
development of regulatory T cells has been reported to
be tightly linked to that of Th17 cells. Both cell lineages
share common developmental pathways (Bettini &
Vignali, 2009 ; Crome et al. 2010). Also Foxp3-lineage-
committed regulatory T cells were directly converted
into IL-17-expressing cells by CpG treatment and
interestingly IDO acts as a pivotal molecular switch in
this process. Only in the absence of IDO does this
conversion occur, whereas it was blocked when IDO
was active (Baban et al. 2009). Although IDO activation
and abnormal tryptophan breakdown is thought to
play a role in SCZ, we were unable to ﬁnd in the
present study a correlation between percentages of
regulatory T cells and those of Th17 cells.
With regard to clinical characteristics we found
that a high regulatory T-cell percentage on admission
correlated with a better clinical outcome (GAF score)
at discharge. Interestingly, in this respect, is that IL-10,
one of the key cytokines produced by regulatory
T cells, has direct eﬀects on brain function and is able
to dampen down sickness behaviour (Richwine et al.
2009). However, eﬀects of regulatory T cells could
also be mediated by direct suppression of the pro-
inﬂammatory immune forces in the brain, e.g. those
exerted by pro-inﬂammatory microglia.
However, and with regard to this clinical eﬀect, a
limitation of our study is that it was not designed to
investigate parameters of prediction and p values
did not reach signiﬁcance with Bonferroni correction.
Suﬃce to say that a study on the predictive value of
regulatory T cells for outcome in psychosis in a larger
group of patients is now imperative.
Our study also has other limitations. We only used
peripheral blood samples and we were not able to
investigate the cerebrospinal ﬂuid (CSF). Pathological
abnormalities of the brain are probably directly re-
ﬂected in the CSF, and indeed in SCZ there are reports
on cell aberrations in CSF. A recent paper investigated
T-cell subsets in CSF and peripheral blood of patients
with a major psychiatric disorder and found an over-
lapping low-grade inﬂammation in CSF as well as in
peripheral blood (Maxeiner et al. 2008). Unfortunately,
we were unable to obtain CSF samples from our
patients.
Furthermore, our study has a small sample size
and outcomes should be replicated on a larger and in-
dependent sample size. The study subjects were the
same in which the monocyte signature was deter-
mined, and it could be that this sample of SCZ patients
has an extreme activation of the immune system. How-
ever, we have found a similar strong inﬂammatory
monocyte signature in patients with mania (Drexhage
et al. 2010b ; Padmos et al. 2008) and in postpartum
psychosis (V. Bergink, unpublished observations). In
the latter conditions the T-cell systemwas not activated
(V. Bergink, unpublished observations).
Our study is naturalistic and all patients (except
one) were on very recently started antipsychotic
medication. As antipsychotic medication exerts anti-
inﬂammatory eﬀects (Drzyzga et al. 2006 ; Pollmacher
et al. 2000 ; Rybakowski, 2000), this eﬀect on outcome
cannot be ruled out (Drexhage et al. 2010b ; Padmos
et al. 2008). Moreover, there were more male partici-
pants than female participants in this study. Although
HC were age- and gender-matched, we cannot com-
pletely rule out a general eﬀect of gender on the acti-
vation state of monocytes and/or T cells. Moreover,
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we cannot rule out a general eﬀect of smoking in this
study sample because there was a diﬀerence in the
smoking status of the patients (69%) vs. our HC (35%).
However, we did not ﬁnd a correlation for smoking
with one of the other immune parameters.
A further limitation is that our FACS data represent
percentages, not the number, of cells within the
lymphocyte population. We were unable to give absol-
ute cell numbers, since we had not performed a leuko-
cyte count in the same blood sample as used for FACS,
although leukocyte counts routinely performed in the
patients at the same time did not show abnormalities.
Taken together, our data do not support the concept
that the T-cell system is in a simple pro-inﬂammatory
state (our hypothesis), but do show that the monocyte
and T-cell networks are activated in recent-onset SCZ
and involve both pro- and anti-inﬂammatory forces.
The question remains as to when and why these
activated set points are installed and what the conse-
quences are for the pathology of SCZ. Here the animal
models of the disease might become important tools
for further study. In rodents chronic immune acti-
vation in the peri-natal period by reagents mimicking
infections with commensal bacteria and viruses
(such as LPS and GpC) do lead to altered set points of
the inﬂammatory systemwhich cause abnormalities in
brain development and consequent psychosis-related
behaviour (Makinodan et al. 2008 ; O’Mahony et al.
2009). Further studies in these animal models into ab-
errant set points of their macrophage/T-cell system
are indicated.
Note
Supplementary material accompanies this paper on
the Journal’s website (http://journals.cambridge.org/
pnp).
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